echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > BeiGene's CD3/CD19 dual-antibody new indications will be included in the priority review

    BeiGene's CD3/CD19 dual-antibody new indications will be included in the priority review

    • Last Update: 2021-03-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 17, BeiGene submitted a new indication of belintoomab for injection marketing application on the grounds of "new varieties, dosage forms and specifications of children’s drugs that meet the physiological characteristics of children, and drugs that meet conditional approval".


    Belintoomab is a bispecific antibody targeting CD3-CD19 developed based on Amgen's most advanced bispecific T cell adapter system (BiTE®).


    Belinto Oumab was approved by the NMPA on December 4 last year through the priority review method for the treatment of adult relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL).


    Belintoux received accelerated FDA approval for marketing as early as December 2014.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.